A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Venetoclax (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 15 Nov 2017 Phase 2 has been added in to the study since treatment arms (3 to 4) and planned patients number are increases. Trial focus also changed.
- 15 Nov 2017 Planned number of patients changed from 84 to 166.
- 15 Nov 2017 Planned End Date changed from 26 Dec 2018 to 29 Dec 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History